7Baggers

CRISPR Therapeutics AG
(NASDAQ:CRSP) 

CRSP stock logo

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technolo...

Founded: 1987
Full Time Employees: 458 (Dec 2022)
Sector: Healthcare
Industry: Biotechnology
PharmaceuticalsGene EditingGenomics
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 
                                          
      revenue:
    		                                      
      collaboration revenue
    		1,000,000         200,000,000  70,000,000 100,000,000 6,000 94,000 158,000 178,000 12,348,000 329,000 900,202,000 202,000 194,000 148,000 44,000 157,000 77,016,000 211,928,000 318,000 328,000 563,000 1,088,000 1,358,000 32,325,000 2,387,000 3,582,000 2,703,000 2,344,000 1,549,000 
      grant revenue
    		458,000 864,000 889,000 892,000 865,000 691,000 602,000 517,000 504,000        762,000 551,000 495,000 499,000 337,000                  
      total revenue
    		1,458,000 864,000 889,000 892,000 865,000 35,691,000 602,000 517,000 504,000 201,206,000  70,000,000 100,000,000 6,000 94,000 158,000 940,000 12,899,000 824,000 900,701,000 539,000                  
      yoy
    		68.55% -97.58% 47.67% 72.53% 71.63% -82.26% NaN% -99.26% -99.50% 3353333.33% NaN% 44203.80% 10538.30% -99.95% -88.59% -99.98% 74.40%                      
      qoq
    		68.75% -2.81% -0.34% 3.12% -97.58% 5828.74% 16.44% 2.58% -99.75% NaN% NaN% -30.00% 1666566.67% -93.62% -40.51% -83.19% -92.71% 1465.41% -99.91% 167005.94%                   
      operating expenses:
    		                                      
      research and development
    		68,574,000 83,526,000 58,902,000 69,894,000 72,484,000 82,155,000 82,160,000 80,165,000 76,172,000 95,144,000 90,698,000 101,555,000 99,935,000 103,555,000 116,622,000 123,223,000 118,245,000 134,470,000 105,321,000 108,277,000 90,565,000 82,365,000 71,008,000 59,380,000 54,193,000 48,761,000 57,246,000 39,533,000 33,822,000 39,820,000 25,633,000 19,519,000 20,030,000 17,845,000 17,120,000 14,805,000 15,572,000 12,052,000 
      general and administrative
    		17,183,000 18,399,000 16,931,000 18,916,000 19,296,000 18,124,000 17,419,000 19,481,000 17,953,000 16,479,000 18,291,000 19,032,000 22,360,000 21,169,000 27,001,000 26,273,000 28,021,000 24,127,000 24,352,000 29,806,000 24,517,000 25,766,000 21,539,000 21,353,000 19,550,000 17,272,000 15,519,000 15,768,000 14,929,000 10,175,000 12,741,000 8,836,000 11,323,000 8,112,000 7,768,000 8,642,000 12,082,000 4,107,000 
      collaboration expense
    		45,949,000 53,703,000 57,115,000 45,153,000 57,509,000  11,153,000 52,131,000 46,966,000 20,000,000 23,422,000 44,636,000 42,192,000 6,823,000 38,859,000 33,922,000 30,646,000                      
      total operating expenses
    		131,706,000 155,628,000 132,948,000 230,216,000 149,289,000 100,279,000 110,732,000 151,777,000 141,091,000 131,623,000 132,411,000 165,223,000 164,487,000 131,547,000 182,482,000 183,418,000 176,912,000 158,597,000 129,673,000 138,083,000 115,082,000 108,131,000 92,547,000 80,733,000 73,743,000 66,033,000 72,765,000 55,301,000 48,751,000 49,995,000 38,374,000 28,355,000 31,353,000 25,957,000 24,888,000 23,447,000 27,654,000 16,159,000 
      income from operations
    		-130,248,000 -154,764,000 -132,059,000 -229,324,000 -148,424,000 -64,588,000 -110,130,000 -151,260,000 -140,587,000 69,583,000 -132,411,000 -95,223,000 -64,487,000 -131,541,000 -182,388,000 -183,260,000 -175,972,000 -145,698,000 -128,849,000 762,618,000 -114,543,000 -107,761,000 -92,399,000 -80,689,000 -73,586,000 10,983,000 139,163,000 -54,983,000 -48,423,000 -49,432,000 -37,286,000 -26,997,000 972,000 -23,570,000 -21,306,000 -20,744,000 -25,310,000 -14,610,000 
      yoy
    		-12.25% 139.62% 19.91% 51.61% 5.57% -192.82% -16.83% 58.85% 118.01% -152.90% -27.40% -48.04% -63.35% -9.72% 41.55% -124.03% 53.63% 35.20% 39.45% -1045.13% 55.66% -1081.16% -166.40% 46.75% 51.96% -122.22% -473.23% 103.66% -5081.79% 109.72% 75.00% 30.14% -103.84% 61.33%     
      qoq
    		-15.84% 17.19% -42.41% 54.51% 129.80% -41.35% -27.19% 7.59% -302.04% -152.55% 39.05% 47.66% -50.98% -27.88% -0.48% 4.14% 20.78% 13.08% -116.90% -765.79% 6.29% 16.63% 14.51% 9.65% -770.00% -92.11% -353.10% 13.55% -2.04% 32.58% 38.11% -2877.47% -104.12% 10.63% 2.71% -18.04% 73.24%  
      operating margin %
    		-8933.33% -17912.50% -14854.78% -25708.97% -17158.84% -180.96% -18294.02% -29257.25% -27894.25% 34.58% NaN% -136.03% -64.49% -2192350.00% -194029.79% -115987.34% -18720.43% -1129.53% -15637.01% 84.67% -21251.02% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      other income:
    		                                      
      other income
    		8,156,000 24,765,000 26,237,000 22,067,000 13,537,000 27,977,000 25,064,000 26,139,000 24,720,000 19,997,000 20,671,000 18,406,000 12,742,000 11,490,000 7,264,000 3,544,000 363,000 2,197,000 1,101,000 750,000 1,955,000 575,000 160,000 1,412,000 4,232,000 19,563,000 2,964,000 2,381,000 1,125,000 -130,000 155,000 -126,000 41,000 -71,000 -161,000 -6,000 78,653,000 -75,000 
      total other income
    		8,156,000 24,765,000 26,237,000 22,067,000 13,537,000 27,977,000 25,064,000 26,139,000 24,720,000 19,997,000 20,671,000 18,406,000 12,742,000 11,490,000 7,264,000 3,544,000 363,000 2,197,000 1,101,000 750,000 1,955,000 575,000 160,000 1,412,000 4,232,000 19,563,000 -466,000 1,369,000 100,000   -1,217,000 -412,000 -430,000 -666,000 -452,000 42,808,000 -76,000 
      net loss before income taxes
    		-122,092,000 -129,999,000 -105,822,000 -207,257,000 -134,887,000 -36,611,000 -85,066,000 -125,121,000 -115,867,000 -60,075,500 -111,740,000 -76,817,000 -51,745,000    -175,609,000    -112,588,000   -79,277,000 -69,354,000   -53,614,000           
      provision for income taxes
    		-839,000 -614,000 -619,000 -1,292,000 -1,109,000 -721,750 -876,000 -1,287,000 -724,000   -923,000 -1,320,000   -6,118,000 -3,608,000   -4,143,000 -575,000 147,000 -200,000 -379,000 -377,000 -4,000 -274,000 -85,000           
      net income
    		-122,931,000 -130,613,000 -106,441,000 -208,549,000 -135,996,000 -37,311,000 -85,942,000 -126,408,000 -116,591,000 89,347,000 -112,152,000 -77,740,000 -53,065,000 -110,575,000 -174,549,000 -185,834,000 -179,217,000 -141,248,000 -127,153,000 759,225,000 -113,163,000 -107,039,000 -92,439,000 -79,656,000 -69,731,000 30,542,000 138,423,000 -53,699,000 -48,408,000 -50,711,000 -38,380,000 -28,300,000 141,000 -24,707,000 -22,315,000 -21,475,000 17,098,000 -14,694,000 
      yoy
    		-9.61% 250.07% 23.85% 64.98% 16.64% -141.76% -23.37% 62.60% 119.71% -180.80% -35.75% -58.17% -70.39% -21.72% 37.27% -124.48% 58.37% 31.96% 37.55% -1053.13% 62.29% -450.46% -166.78% 48.34% 44.05% -160.23% -460.66% 89.75% -34431.91% 105.25% 71.99% 31.78% -99.18% 68.14%     
      qoq
    		-5.88% 22.71% -48.96% 53.35% 264.49% -56.59% -32.01% 8.42% -230.49% -179.67% 44.27% 46.50% -52.01% -36.65% -6.07% 3.69% 26.88% 11.09% -116.75% -770.91% 5.72% 15.79% 16.05% 14.23% -328.31% -77.94% -357.78% 10.93% -4.54% 32.13% 35.62% -20170.92% -100.57% 10.72% 3.91% -225.60% -216.36%  
      net income margin %
    		-8431.48% -15117.25% -11973.12% -23379.93% -15722.08% -104.54% -14276.08% -24450.29% -23133.13% 44.41% NaN% -111.06% -53.06% -1842916.67% -185690.43% -117616.46% -19065.64% -1095.03% -15431.19% 84.29% -20994.99% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% 
      foreign currency translation adjustment
    		-32,000 1,000 -28,000 80,000 41,000 -87,000 76,000 2,000 -11,000 61,000 -49,000 28,000 32,000 115,000 -100,000 -69,000 -27,000 3,000 -24,000 5,000 5,000 37,000 31,000 -3,000 -25,000 29,000 -12,000 -10,000 8,000 -6,000 -21,000 12,000 2,000 8,000 6,000 24,000  -1,000 
      unrealized gain on marketable securities
    		-6,730,000 -166,000 973,000 -174,000 2,254,000 -8,638,000 13,368,000 -1,329,000 -3,454,000 8,649,000 2,160,000 452,000 6,227,000                          
      comprehensive loss
    		-129,693,000 -130,778,000 -105,496,000 -208,643,000 -133,701,000 -46,036,000 -72,498,000 -127,735,000 -120,056,000 -58,526,750 -110,041,000 -77,260,000 -46,806,000    -191,043,000    -113,541,000   -79,659,000 -69,756,000   -53,709,000 -48,400,000 -50,717,000 -38,401,000 -28,288,000 143,000 -24,699,000 -22,309,000 -21,451,000 17,098,000 -14,695,000 
      net loss per common share — basic
    		-1,280 -1,350 -1,170 -2,400 -1,580 -420 -1,010 -1,490 -1,430 -767.5 -1,410 -980 -670    -2,320    -1,510                  
      basic weighted-average common shares outstanding
    		96,051,228,000 89,925,109,000 91,305,337,000 87,069,690,000 85,938,720,000 84,359,126,000 85,234,926,000 84,920,929,000 81,794,630,000 79,220,930,000 79,414,098,000 79,091,061,000 78,676,986,000 77,746,575,000 78,021,520,000 77,513,327,000 77,098,319,000 75,948,686,000 76,288,534,000 75,826,594,000 75,005,187,000 65,949,672,000 70,143,481,000                
      net loss per common share — diluted
    		-1,280 -1,350 -1,170 -2,400 -1,580 -420 -1,010 -1,490 -1,430 -767.5 -1,410 -980 -670    -2,320    -1,510                  
      diluted weighted-average common shares outstanding
    		96,051,228,000 89,925,109,000 91,305,337,000 87,069,690,000 85,938,720,000 84,359,126,000 85,234,926,000 84,920,929,000 81,794,630,000 79,220,930,000 79,414,098,000 79,091,061,000 78,676,986,000 77,746,575,000 78,021,520,000 77,513,327,000 77,098,319,000 80,393,496,000 76,288,534,000 80,449,956,000 75,005,187,000 65,949,672,000 70,143,481,000                
      acquired in-process research and development
    		   96,253,000                                   
      benefit for income taxes
    		         -233,000 -412,000   9,476,000 575,000   -1,030,750 595,000                    
      net income before income taxes
    		             -120,051,000 -175,124,000 -179,716,000  -143,501,000 -127,748,000 763,368,000  -107,186,000 -92,239,000   30,546,000 138,697,000  -48,323,000 -50,574,000 -38,284,000 -28,214,000 -16,792,000 -24,000,000 -21,972,000 -21,196,000   
      unrealized loss on marketable securities
    		             6,501,000 -1,820,000 -3,380,000 -11,799,000 -4,300,000 -117,000 -173,000 -383,000 14,000 -144,000                
      comprehensive income
    		             -103,959,000 -176,469,000 -189,283,000  -145,545,000 -127,294,000 759,057,000  -106,988,000 -92,552,000   30,571,000 138,411,000            
      net income per common share — basic
    		             -1,400 -2,240 -2,400  -1,880 -1,670 10,010  -1,520 -1,320                
      net income per common share — diluted
    		             -1,400 -2,240 -2,400  -1,740 -1,670 9,440  -1,520 -1,320                
      loss from equity method investment
    		                          -3,430,000 -1,012,000           
      including the following revenue from a related party, see notes 7 & 12:
    		                                      
      including the following research and development expense with a related party, see notes 7 & 12:
    		                                      
      net income per share
    		                       -1.3 -1.15 0.55 2.52 -1.01 -0.93 -1.07 -0.82 -0.62 0.01 -0.62 -0.56 -0.54 5.54 -2.77 
      weighted-average common shares outstanding used in net loss per share attributable to common shareholders—basic and diluted
    		                       61,420,746 60,847,683   53,188,041           
      including the following revenue from a related party, see notes 5 & 10:
    		                                      
      including the following research and development expense with a related party, see notes 5 & 10:
    		                                      
      reconciliation of net income to net income attributable to common shareholders:
    		                                      
      weighted-average common shares outstanding used in net income (loss) per share attributable to common shareholders—basic
    		                         54,392,304 54,829,057            
      weighted-average common shares outstanding used in net income (loss) per share attributable to common shareholders—diluted
    		                         56,932,798 57,598,901            
      including the following revenue from a related party, see notes 6 & 11:
    		                         53,143.5 211,928 318 328          
      including the following research and development expense with a related party, see notes 6 & 11:
    		                         8,005.5 17,563 6,870 7,587          
      reconciliation of net loss to net loss attributable to common shareholders:
    		                                      
      income from equity method investment
    		                            -1,025,000 -1,012,000 -1,153,000 -1,091,000 -453,000 -359,000 -505,000 -446,000 -35,846,000  
      benefit from income taxes
    		                            -85,000 -137,000 -96,000 -86,000 -419,000 -707,000 -343,000 -279,000   
      weighted-average common shares outstanding used in net income per share attributable to common shareholders—basic and diluted
    		                            52,093,208 47,391,988 46,842,316 45,877,428 40,057,365 40,088,718 39,895,938 39,725,947 12,257,483 5,292,348 
      other
    		                                      
      total other (expense)
    		                             -1,142,000 -998,000        
      including the following revenue from a related party, see notes 6 & 10:
    		                             443         
      including the following research and development expense with a related party, see notes 6 & 10:
    		                             418         
      including the following revenue from a related party, see note 10:
    		                              881 1,082       
      including the following research and development expense with a related party, see note 10:
    		                              1,246 1,106       
      interest expense
    		                                    1,000 -1,000 
      gain on extinguishment of convertible loan
    		                                      
      loss attributable to noncontrolling interest
    		                                    1,000 14,000 
      net income attributable to common shareholders
    		                                141,000 -24,707,000 -22,315,000 -21,475,000 17,099,000 -14,680,000 
      including the following revenue from a related party, see note 11:
    		                                972 1,249 1,475    
      including the following research and development expense with a related party, see note 11:
    		                                924.75 1,208 1,355    
      including the following amounts of revenue from a related party, see note 11:
    		                                   1,164   
      including the following amounts of research and development expense with a related party, see note 11:
    		                                   1,136   
      net income before benefit from income taxes
    		                                    17,498,000 -14,686,000 
      (benefit from) benefit from income taxes
    		                                    -400,000 -8,000 
      including the following amounts of revenue from a related party, see note 13:
    		                                    96.25 385 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 
                                            
        assets
      		                                      
        current assets:
      		                                      
        cash and cash equivalents
      		423,308,000 347,559,000 286,497,000 193,618,000 235,184,000 298,257,000 225,670,000 484,472,000 707,427,000 389,477,000 527,765,000 444,796,000 344,407,000 211,885,000 494,151,000 496,893,000 683,906,000 923,031,000 1,011,548,000 1,646,646,000 1,126,059,000 1,168,620,000 1,041,417,000 945,068,000 889,712,000 943,771,000 629,717,000 427,885,000 437,549,000          
        marketable securities
      		2,018,477,000 1,628,269,000 1,629,213,000 1,527,619,000 1,620,101,000 1,605,569,000 1,709,975,000 1,517,147,000 1,400,698,000 1,304,215,000 1,212,061,000 1,323,307,000 1,538,763,000 1,603,433,000 1,401,824,000 1,568,446,000 1,537,355,000 1,456,098,000 1,465,812,000 942,800,000 680,144,000 521,713,000 324,573,000                
        prepaid expenses and other current assets
      		6,577,000 9,843,000 13,382,000 12,429,000 12,326,000 8,306,000 8,246,000 8,788,000 11,499,000 14,386,000 20,760,000 21,469,000 24,796,000 37,708,000 36,679,000 41,651,000 39,212,000 38,079,000 41,423,000 31,347,000 26,006,000 26,143,000 24,839,000 20,517,000 14,453,000            1,511,000 946,000 
        total current assets
      		2,448,362,000 1,985,671,000 1,929,092,000 1,733,666,000 1,867,611,000 1,937,132,000 1,943,891,000 2,010,407,000 2,119,624,000 1,908,078,000 1,760,586,000 1,859,572,000 1,907,966,000 1,853,026,000 1,932,703,000 2,107,056,000 2,260,616,000 2,417,513,000 2,518,935,000 2,620,943,000 1,832,359,000 1,716,620,000 1,390,939,000 965,618,000 929,282,000 987,547,000 664,065,000 438,473,000 449,796,000 496,688,000 330,549,000 351,478,000 248,385,000 258,586,000 281,285,000 296,462,000 320,188,000 231,651,000 
        property and equipment
      		112,175,000 115,851,000 120,831,000 124,926,000 129,426,000 134,093,000 138,542,000 143,031,000 147,253,000 151,945,000 156,122,000 159,172,000 162,198,000 163,634,000 166,110,000 165,194,000 157,453,000 137,575,000 105,883,000 75,414,000 51,913,000 42,160,000 37,924,000 34,444,000 31,773,000 31,330,000 21,074,000 20,156,000 18,871,000 18,097,000 18,395,000 18,907,000 18,857,000 19,564,000 19,927,000 22,165,000 21,027,000 3,862,000 
        restricted cash
      		7,629,000 7,629,000 8,006,000 8,006,000 8,006,000 11,519,000 11,520,000 11,520,000 11,516,000 11,591,000 11,830,000 11,799,000 11,717,000 11,635,000 12,123,000 12,123,000 12,123,000 16,913,000 16,848,000 18,071,000 16,844,000 16,848,000 16,845,000 6,303,000 5,041,000 5,041,000 3,915,000 3,915,000 3,163,000 3,165,000 3,165,000 3,165,000 3,154,000 3,154,000 3,154,000 3,151,000 3,150,000 3,153,000 
        operating lease assets
      		128,671,000 131,724,000 134,659,000 137,641,000 140,277,000 143,461,000 146,286,000 148,538,000 151,254,000 153,993,000 156,215,000 159,352,000 153,346,000 156,921,000 161,507,000 166,740,000 171,541,000 174,460,000 175,132,000 179,381,000 50,129,000 50,865,000 38,454,000 39,297,000 40,321,000 41,502,000 30,619,000 30,770,000 25,098,000          
        other non-current assets
      		28,983,000 24,368,000 24,308,000 25,472,000 20,782,000 15,829,000 15,891,000 15,141,000 9,368,000 1,975,000 2,047,000 2,175,000 2,760,000 4,640,000 3,682,000 3,760,000 4,330,000 5,291,000 4,788,000 5,557,000 6,498,000 1,293,000 662,000 662,000 662,000 1,097,000 668,000 669,000 669,000 650,000 704,000 571,000 606,000 657,000 237,000 183,000 198,000 3,888,000 
        total assets
      		2,725,820,000 2,265,243,000 2,245,308,000 2,029,711,000 2,166,102,000 2,242,034,000 2,256,130,000 2,339,853,000 2,439,017,000 2,229,571,000 2,086,830,000 2,197,014,000 2,244,364,000 2,243,057,000 2,353,356,000 2,463,363,000 2,606,175,000 2,751,877,000 2,821,725,000 2,899,519,000 1,957,910,000 1,827,966,000 1,485,018,000 1,046,532,000 1,007,300,000 1,066,752,000 720,590,000 494,245,000 497,873,000 518,903,000 353,130,000 374,452,000 271,346,000 282,319,000 304,975,000 322,346,000 344,962,000 278,653,000 
        liabilities and shareholders’ equity
      		                                      
        current liabilities:
      		                                      
        accounts payable
      		13,647,000 11,138,000 11,798,000 9,753,000 13,064,000 14,709,000 15,578,000 9,452,000 16,463,000 38,147,000 26,152,000 27,588,000 45,153,000 27,428,000 32,114,000 25,244,000 27,111,000 14,816,000 10,167,000 10,145,000 13,072,000 9,094,000 19,020,000 13,219,000 11,277,000 5,944,000 3,374,000 7,143,000 7,131,000 5,221,000 4,479,000 2,546,000 1,639,000 2,116,000 2,559,000 3,937,000 4,569,000 1,943,000 
        accrued expenses
      		74,932,000 89,407,000 84,182,000 73,738,000 84,615,000 41,072,000 47,204,000 91,883,000 76,432,000 45,335,000 66,405,000 89,838,000 85,631,000 77,682,000 102,954,000 82,223,000 72,632,000 91,003,000 68,303,000 67,101,000 49,864,000 53,782,000 35,445,000 36,685,000 21,924,000             12,402,000 
        deferred revenue, current
      		15,344,000 15,771,000 1,295,000 2,129,000 3,021,000 3,845,000 4,483,000 4,759,000 4,072,000 4,105,000 3,500,000       1,011,000 1,562,000 2,071,000 1,802,000 2,341,000 610,000 759,000 803,000              
        accrued tax liabilities
      		638,000 1,113,000 3,426,000 715,000 1,241,000 451,000 838,000 454,000 1,207,000 438,000 176,000 558,000 273,000 135,000 4,272,000 3,953,000 2,608,000 724,000 3,265,000 4,463,000 3,356,000 10,473,000 6,348,000 1,507,000 284,000 583,000 1,478,000 542,000 615,000 24,000 47,000 433,000 347,000 427,000 272,000 190,000 23,000 82,000 
        operating lease liabilities
      		18,612,000 18,578,000 18,256,000 18,027,000 17,506,000 17,288,000 16,883,000 16,451,000 15,992,000 15,625,000 15,001,000 14,833,000 15,717,000 15,842,000 11,260,000 8,267,000 11,076,000 12,158,000 12,641,000 15,875,000 12,063,000 11,362,000 10,640,000 9,906,000 9,005,000 8,489,000 4,805,000 4,880,000 4,899,000          
        other current liabilities
      		13,113,000 13,113,000    10,417,000 4,824,000 4,824,000 4,824,000 5,141,000  20,000 20,000 20,000 270,000 270,000 270,000 171,000 268,000 268,000 2,933,000 7,207,000 12,086,000 12,429,000 11,793,000 10,950,000  219,000 73,000 171,000 226,000 162,000 137,000 62,000 68,000 62,000 59,000 62,000 
        total current liabilities
      		136,286,000 149,120,000 118,957,000 104,362,000 119,447,000 87,782,000 89,810,000 127,823,000 118,990,000 108,791,000 111,234,000 132,837,000 146,794,000 121,107,000 150,870,000 119,957,000 113,697,000 119,883,000 96,206,000 99,923,000 83,090,000 94,259,000 84,149,000 74,505,000 55,086,000 57,106,000 79,779,000 31,412,000 28,398,000 32,278,000 18,481,000 14,395,000 14,511,000 12,117,000 15,814,000 16,915,000 21,998,000 78,097,000 
        long-term debt
      		585,470,000                                      
        operating lease liabilities, net of current portion
      		183,560,000 188,168,000 192,768,000 197,425,000 201,852,000 206,405,000 210,662,000 214,852,000 218,935,000 223,007,000 226,585,000 230,342,000 224,552,000 228,179,000 230,895,000 234,160,000 227,904,000 212,872,000 192,734,000 175,329,000 49,408,000 50,067,000 38,570,000 40,317,000 42,390,000 44,050,000 36,827,000 37,200,000 31,728,000          
        other non-current liabilities
      		5,948,000 6,142,000 5,278,000 4,476,000 3,320,000 3,444,000 3,677,000 3,646,000 3,615,000 958,000 5,394,000 5,484,000 5,799,000 5,969,000 5,314,000 6,092,000 7,335,000 7,339,000 8,086,000 8,697,000 8,138,000 7,630,000 7,222,000 9,264,000 11,951,000 14,395,000 235,000 220,000 182,000 273,000 283,000 298,000 314,000 175,000 198,000 177,000 189,000 574,000 
        total liabilities
      		911,264,000 343,430,000 329,326,000 318,586,000 336,942,000 309,954,000 316,472,000 358,904,000 355,081,000 346,768,000 359,036,000 380,986,000 389,468,000 367,578,000 399,402,000 372,532,000 361,259,000 352,417,000 308,802,000 295,724,000 152,412,000 163,732,000 141,717,000 135,862,000 121,203,000 127,327,000 128,712,000 126,562,000 118,063,000 101,589,000 87,976,000 84,117,000 83,514,000 103,361,000 107,172,000 107,171,000 112,116,000 155,620,000 
        commitments and contingencies, see note 7
      		                                      
        shareholders’ equity:
      		                                      
        common shares, chf 0.03 nominal value, 132,477,166 shares authorized at march 31, 2026 and at december 31, 2025, 96,500,822 and 96,009,657 shares issued at march 31, 2026 and december 31, 2025, respectively, 96,385,506 and 95,894,341 shares outstanding at march 31, 2026 and december 31, 2025, respectively
      		3,115,000                                      
        treasury shares, at cost, 115,316 shares at march 31, 2026 and at december 31, 2025
      		-60,000                                      
        additional paid-in capital
      		3,883,924,000 3,861,516,000 3,724,981,000 3,414,849,000 3,324,314,000 3,293,556,000 3,255,112,000 3,223,924,000 3,199,183,000 2,878,155,000 2,821,225,000 2,799,420,000 2,761,050,000 2,734,838,000 2,709,361,000 2,669,782,000 2,634,597,000 2,598,114,000 2,566,057,000 2,529,649,000 2,490,421,000 2,235,679,000 1,807,878,000 1,282,952,000 1,178,770,000 1,162,345,000 845,526,000 759,796,000 718,255,000 659,776,000 457,032,000 443,774,000 312,018,000 303,292,000 297,446,000 292,519,000 288,739,000 11,553,000 
        accumulated deficit
      		-2,070,482,000 -1,947,551,000 -1,816,938,000 -1,710,497,000 -1,501,948,000 -1,365,952,000 -1,328,641,000 -1,242,699,000 -1,116,291,000 -999,700,000 -1,089,047,000 -976,895,000 -899,155,000 -846,090,000 -735,515,000 -560,966,000 -375,132,000 -195,915,000 -54,667,000  -686,739,000 -573,576,000 -466,537,000 -374,098,000 -294,442,000 -224,711,000 -255,253,000 -393,676,000 -339,977,000 -243,979,000 -193,268,000 -154,888,000 -125,440,000 -125,580,000 -100,873,000 -78,558,000 -57,083,000 -74,182,000 
        accumulated other comprehensive income
      		-1,941,000 4,821,000 4,986,000 4,041,000 4,135,000 1,840,000 10,565,000 -2,879,000 -1,552,000 1,913,000            -83,000 -134,000 -21,000 -18,000 7,000    -1,000 5,000 26,000 14,000 12,000 4,000    
        total shareholders’ equity
      		1,814,556,000 1,921,813,000 1,915,982,000 1,711,125,000  1,932,080,000    1,882,803,000    1,875,479,000    2,399,460,000    1,664,234,000           187,832,000  197,803,000 215,175,000 232,846,000  
        total liabilities and shareholders’ equity
      		2,725,820,000 2,265,243,000 2,245,308,000 2,029,711,000 2,166,102,000 2,242,034,000 2,256,130,000 2,339,853,000 2,439,017,000 2,229,571,000 2,086,830,000 2,197,014,000 2,244,364,000 2,243,057,000 2,353,356,000 2,463,363,000 2,606,175,000 2,751,877,000 2,821,725,000 2,899,519,000 1,957,910,000 1,827,966,000 1,485,018,000 1,046,532,000 1,007,300,000 1,066,752,000 720,590,000 494,245,000 497,873,000 518,903,000 353,130,000 374,452,000 271,346,000 282,319,000 304,975,000 322,346,000   
        accounts receivable
      		     25,000,000    200,000,000  70,000,000   49,000 66,000 143,000 305,000 152,000 150,000 150,000 144,000 110,000 33,000 25,117,000              
        deferred revenue, non-current
      		  12,323,000 12,323,000 12,323,000 12,323,000 12,323,000 12,583,000 13,541,000 14,012,000 15,823,000 12,323,000 12,323,000 12,323,000 12,323,000 12,323,000 12,323,000 12,323,000 11,776,000 11,775,000 11,776,000 11,776,000 11,776,000 11,776,000 11,776,000              
        commitments and contingencies
      		                                      
        common shares, chf 0.03 nominal value, 132,477,166 shares authorized at december 31, 2025 and december 31, 2024, 96,009,657 and 85,912,297 shares issued at december 31, 2025 and december 31, 2024, respectively, 95,894,341 and 85,741,981 shares outstanding at december 31, 2025 and december 31, 2024, respectively
      		 3,087,000                                     
        treasury shares, at cost, 115,316 and 170,316 shares at december 31, 2025 and december 31, 2024, respectively
      		 -60,000                                     
        marketable securities, non-current
      		  28,412,000     11,216,000  1,973,000  4,901,000 6,320,000 53,130,000 77,147,000 8,392,000                       
        common shares, chf 0.03 nominal value, 132,477,166 shares authorized at september 30, 2025 and at december 31, 2024, 93,998,110 and 85,912,297 shares issued at september 30, 2025 and december 31, 2024, respectively, 93,872,794 and 85,741,981 shares outstanding at september 30, 2025 and december 31, 2024, respectively
      		  3,013,000                                    
        treasury shares, at cost, 125,316 and 170,316 shares at september 30, 2025 and december 31, 2024, respectively
      		  -60,000                                    
        common shares, chf 0.03 nominal value, 132,477,166 shares authorized at june 30, 2025 and at december 31, 2024, 88,546,755 and 85,912,297 shares issued at june 30, 2025 and december 31, 2024, respectively, 88,376,439 and 85,741,981 shares outstanding at june 30, 2025 and december 31, 2024, respectively
      		   2,794,000                                   
        treasury shares, at cost, 170,316 shares at june 30, 2025 and at december 31, 2024
      		   -62,000                                   
        common shares, chf 0.03 nominal value, 132,477,166 shares authorized at march 31, 2025 and at december 31, 2024, 86,531,240 and 85,912,297 shares issued at march 31, 2025 and december 31, 2024, respectively, 86,360,924 and 85,741,981 shares outstanding at march 31, 2025 and december 31, 2024, respectively
      		    2,721,000                                  
        treasury shares, at cost, 170,316 shares at march 31, 2025 and at december 31, 2024
      		    -62,000                                  
        total shareholders' equity
      		    1,829,160,000  1,939,658,000 1,980,949,000 2,083,936,000  1,727,794,000 1,816,028,000 1,854,896,000  1,953,954,000 2,090,831,000 2,244,916,000  2,512,923,000 2,603,795,000 1,805,498,000  1,343,301,000 910,670,000 886,097,000 939,425,000 591,878,000 367,683,000 379,810,000 417,314,000 265,154,000 290,335,000  178,958,000     
        intangible assets
      		        2,000 16,000 30,000 43,000 57,000 71,000 84,000 98,000 112,000 125,000 139,000 153,000 167,000 180,000 194,000 208,000 221,000 235,000 249,000 262,000 276,000 303,000 317,000 331,000 344,000 358,000 372,000 385,000 399,000 413,000 
        common shares, chf 0.03 nominal value, 132,477,166 and 126,536,183 shares authorized at december 31, 2024 and december 31, 2023, respectively, 85,912,297 and 80,214,694 shares issued at december 31, 2024 and december 31, 2023, respectively, 85,741,981 and 80,044,378 shares outstanding at december 31, 2024 and december 31, 2023, respectively
      		     2,698,000                                 
        treasury shares, at cost, 170,316 shares at december 31, 2024 and at december 31, 2023
      		     -62,000                                 
        common shares, chf 0.03 nominal value, 132,477,166 and 126,536,183 shares authorized at september 30, 2024 and december 31, 2023, respectively, 85,506,092 and 80,214,694 shares issued at september 30, 2024 and december 31, 2023, respectively, 85,335,776 and 80,044,378 shares outstanding at september 30, 2024 and december 31, 2023, respectively
      		      2,684,000                                
        treasury shares, at cost, 170,316 shares at september 30, 2024 and at december 31, 2023
      		      -62,000                                
        common shares, chf 0.03 nominal value, 132,477,166 and 126,536,183 shares authorized at june 30, 2024 and december 31, 2023, respectively, 85,215,817 and 80,214,694 shares issued at june 30, 2024 and december 31, 2023, respectively, 85,045,501 and 80,044,378 shares outstanding at june 30, 2024 and december 31, 2023, respectively
      		       2,665,000                               
        treasury shares, at cost, 170,316 shares at june 30, 2024 and at december 31, 2023
      		       -62,000                               
        common shares, chf 0.03 nominal value, 130,452,265 and 126,536,183 shares authorized at march 31, 2024 and december 31, 2023, respectively, 85,007,926 and 80,214,694 shares issued at march 31, 2024 and december 31, 2023, respectively, 84,837,610 and 80,044,378 shares outstanding at march 31, 2024 and december 31, 2023, respectively
      		        2,658,000                              
        treasury shares, at cost, 170,316 shares at march 31, 2024 and at december 31, 2023
      		        -62,000                              
        common shares, chf 0.03 par value, 126,536,183 and 150,347,467 shares authorized at december 31, 2023 and 2022, respectively, 80,214,694 and 78,692,766 shares issued at december 31, 2023 and 2022, respectively, 80,044,378 and 78,512,450 shares outstanding at december 31, 2023 and 2022, respectively
      		         2,497,000                             
        treasury shares, at cost, 170,316 and 180,316 shares at december 31, 2023 and 2022, respectively
      		         -62,000                             
        common shares, chf 0.03 nominal value, 79,607,064 and 78,692,766 shares issued at september 30, 2023 and december 31, 2022, respectively, 79,426,748 and 78,512,450 shares outstanding at september 30, 2023 and december 31, 2022, respectively
      		          2,476,000                            
        treasury shares, at cost, 180,316 shares at september 30, 2023 and at december 31, 2022
      		          -63,000                            
        accumulated other comprehensive loss
      		          -6,797,000 -8,908,000 -9,388,000 -15,647,000 -22,262,000 -20,342,000 -16,893,000 -5,067,000 -770,000 -629,000 -461,000      -22,000 -10,000        -2,000 -26,000 -26,000 
        common shares, chf 0.03 par value, 79,552,682 and 78,692,766 shares issued at june 30, 2023 and december 31, 2022, respectively, 79,372,366 and 78,512,450 shares outstanding at june 30, 2023 and december 31, 2022, respectively
      		           2,474,000                           
        treasury shares, at cost, 180,316 shares at june 30, 2023 and at december 31, 2022
      		           -63,000                           
        common shares, chf 0.03 par value, 150,347,467 shares authorized at march 31, 2023 and at december 31, 2022, 79,044,050 and 78,692,766 shares issued at march 31, 2023 and december 31, 2022, respectively, 78,863,734 and 78,512,450 shares outstanding at march 31, 2023 and december 31, 2022, respectively
      		            2,452,000                          
        treasury shares, at cost, 180,316 shares at march 31, 2023 and at december 31, 2022
      		            -63,000                          
        common shares, chf 0.03 par value, 150,347,467 and 145,364,335 shares authorized at december 31, 2022 and 2021, respectively, 78,692,766 and 77,170,382 shares issued at december 31, 2022 and 2021, respectively, 78,512,450 and 76,990,066 shares outstanding at december 31, 2022 and 2021, respectively.
      		             2,441,000                         
        treasury shares, at cost, 180,316 shares at december 31, 2022 and 2021, respectively
      		             -63,000                         
        commitments and contingencies, see note 6
      		                                      
        common shares, chf 0.03 par value, 150,347,467 and 145,364,335 shares authorized at september 30, 2022 and december 31, 2021, respectively, 78,428,146 and 77,170,382 shares issued at september 30, 2022 and december 31, 2021, respectively, 78,247,830 and 76,990,066 shares outstanding at september 30, 2022 and december 31, 2021, respectively
      		              2,433,000                        
        treasury shares, at cost, 180,316 shares at september 30, 2022 and at december 31, 2021
      		              -63,000                        
        common shares, chf 0.03 par value, 150,347,467 and 145,364,335 shares authorized at june 30, 2022 and december 31, 2021, respectively, 77,972,479 and 77,170,382 shares issued at june 30, 2022 and december 31, 2021, respectively, 77,792,163 and 76,990,066 shares outstanding at june 30, 2022 and december 31, 2021, respectively
      		               2,420,000                       
        treasury shares, at cost, 180,316 shares at june 30, 2022 and at december 31, 2021
      		               -63,000                       
        common shares, chf 0.03 par value, 145,364,335 shares authorized at march 31, 2022 and december 31, 2021, 77,566,721 and 77,170,382 shares issued at march 31, 2022 and december 31, 2021, respectively, 77,386,405 and 76,990,066 shares outstanding at march 31, 2022 and december 31, 2021, respectively
      		                2,407,000                      
        treasury shares, at cost, 180,316 shares at march 31, 2022 and at december 31, 2021
      		                -63,000                      
        common shares, chf 0.03 par value, 145,364,335 and 115,172,786 shares authorized at december 31, 2021 and 2020, respectively, 77,170,382 and 74,110,160 shares issued at december 31, 2021 and 2020, respectively, 76,990,066 and 73,914,844 shares outstanding at december 31, 2021 and 2020, respectively.
      		                 2,391,000                     
        treasury shares, at cost, 180,316 and 195,316 shares at december 31, 2021 and 2020, respectively
      		                 -63,000                     
        common shares, chf 0.03 par value, 145,364,335 and 115,172,786 shares authorized at september 30, 2021 and december 31, 2020, respectively, 76,643,496 and 74,110,160 shares issued at september 30, 2021 and december 31, 2020, respectively, 76,463,180 and 73,914,844 shares outstanding at september 30, 2021 and december 31, 2020, respectively.
      		                  2,366,000                    
        treasury shares, at cost, 180,316 shares at september 30, 2021 and 195,316 at december 31, 2020.
      		                  -63,000                    
        common shares, chf 0.03 par value, 145,364,335 and 115,172,786 shares authorized at june 30, 2021 and december 31, 2020, respectively, 76,273,769 and 74,110,160 shares issued at june 30, 2021 and december 31, 2020, respectively, 76,078,453 and 73,914,844 shares outstanding at june 30, 2021 and december 31, 2020, respectively.
      		                   2,352,000                   
        treasury shares, at cost, 195,316 shares at june 30, 2021 and december 31, 2020.
      		                   -63,000                   
        retained earnings
      		                   72,486,000                   
        common shares, chf 0.03 par value, 115,172,786 shares authorized at march 31, 2021 and december 31, 2020, 75,925,944 and 74,110,160 shares issued at march 31, 2021 and december 31, 2020, respectively, 75,730,628 and 73,914,844 shares outstanding at march 31, 2021 and december 31, 2020, respectively.
      		                    2,340,000                  
        treasury shares, at cost, 195,316 shares at march 31, 2021 and december 31, 2020.
      		                    -63,000                  
        common shares, chf 0.03 par value, 115,172,786 and 103,901,006 shares authorized at december 31, 2020 and 2019, respectively, 74,110,160 and 61,034,025 shares issued at december 31, 2020 and 2019, respectively, 73,914,844 and 60,783,799 shares outstanding at december 31, 2020 and 2019, respectively.
      		                     2,277,000                 
        treasury shares, at cost, 195,316 and 250,226 shares at december 31, 2020 and 2019, respectively
      		                     -63,000                 
        common shares, chf 0.03 par value, 115,172,786 and 103,901,006 shares authorized at september 30, 2020 and december 31, 2019, respectively, 70,799,178 and 61,034,025 shares issued at september 30, 2020 and december 31, 2019, respectively, 70,603,862 and 60,783,799 shares outstanding at september 30, 2020 and december 31, 2019, respectively.
      		                      2,157,000                
        treasury shares, at cost, 195,316 and 250,226 shares at september 30, 2020 and december 31, 2019, respectively.
      		                      -63,000                
        commitments and contingencies, see note 4
      		                                      
        common shares, chf 0.03 par value, 115,172,786 and 103,901,006 shares authorized at june 30, 2020 and december 31, 2019, respectively, 62,747,821 and 61,034,025 shares issued at june 30, 2020 and december 31, 2019, respectively, 62,552,505 and 60,783,799 shares outstanding at june 30, 2020 and december 31, 2019, respectively.
      		                       1,900,000               
        treasury shares, at cost, 195,316 and 250,226 shares at june 30, 2020 and december 31, 2019, respectively.
      		                       -63,000               
        common shares, chf 0.03 par value, 103,901,006 and 103,901,006 shares authorized at march 31, 2020 and december 31, 2019, respectively, 61,122,431 and 61,034,025 shares issued at march 31, 2020 and december 31, 2019, respectively 60,890,035 and 60,783,799 shares outstanding at march 31, 2020 and december 31, 2019, respectively.
      		                        1,850,000              
        treasury shares, at cost, 232,396 and 250,226 shares at march 31, 2020 and december 31, 2019, respectively.
      		                        -63,000              
        accounts receivable, including related party amounts of 0 and 88 as of december 31, 2019 and 2018, respectively
      		                         99,000             
        prepaid expenses and other current assets, including related party amounts of 0 and 3,417 as of december 31, 2019 and 2018, respectively
      		                         43,677,000             
        accrued expenses, including related party amounts of 0 and 1,700 as of december 31, 2019 and 2018, respectively
      		                         30,180,000             
        deferred revenue current, including related party amounts of 0 and 102 as of december 31, 2019 and 2018, respectively
      		                         960,000             
        deferred rent
      		                             1,027,000 1,027,000 1,027,000 1,027,000 1,027,000 1,027,000 1,027,000 1,027,000  
        deferred revenue, including related party amounts of 0 and 57,780 as of december 31, 2019 and 2018, respectively
      		                         11,776,000             
        deferred rent non-current
      		                             11,232,000 11,380,000 11,566,000 11,761,000 11,380,000 11,928,000 11,768,000 12,283,000  
        common shares, chf 0.03 par value, 103,901,006 and 90,343,803 shares authorized at december 31, 2019 and 2018, respectively, 61,034,025 and 52,160,798 shares issued at december 31, 2019 and 2018, respectively, 60,783,799 and 51,852,862 shares outstanding at december 31, 2019 and 2018, respectively.
      		                         1,847,000             
        treasury shares, at cost, 250,226 and 307,936 shares at december 31, 2019 and 2018, respectively
      		                         -63,000             
        accounts receivable, including related party amounts of 39 and 88 as of september 30, 2019 and december 31, 2018, respectively
      		                          39,000            
        prepaid expenses and other current assets, including related party amounts of 28,875 and 3,417 as of september 30, 2019 and december 31, 2018, respectively
      		                          34,309,000            
        accrued expenses, including related party amounts of 4,537 and 1,700 as of september 30, 2019 and december 31, 2018, respectively
      		                          22,397,000            
        deferred revenue current, including related party amounts of 47,725 and 102 as of september 30, 2019 and december 31, 2018, respectively
      		                          47,725,000            
        deferred revenue non-current, including related party amounts of 11,871 and 57,780 as of september 30, 2019 and december 31, 2018, respectively
      		                          11,871,000            
        common shares, chf 0.03 par value, 55,677,088 and 52,183,139 shares authorized at september 30, 2019 and december 31, 2018, respectively, 55,446,359 and 52,160,798 shares issued at september 30, 2019 and december 31, 2018, respectively, 55,189,370 and 51,852,862 shares outstanding at september 30, 2019 and december 31, 2018, respectively, 23,948,128 and 20,498,996 shares in conditional capital at september 30, 2019 and december 31, 2018, respectively.
      		                          1,684,000            
        treasury shares, at cost, 256,989 and 307,936 shares at september 30, 2019 and december 31, 2018, respectively
      		                          -57,000            
        accounts receivable, including related party amounts of 321 and 88 as of june 30, 2019 and december 31, 2018, respectively
      		                           321,000           
        prepaid expenses and other current assets, including related party amounts of 3,318 and 3,417 as of june 30, 2019 and december 31, 2018, respectively
      		                           10,267,000           
        accrued expenses, including related party amounts of 3,312 and 1,700 as of june 30, 2019 and december 31, 2018, respectively
      		                           18,628,000           
        deferred revenue non-current, including related party amounts of 57,730 and 57,780 as of june 30, 2019 and december 31, 2018, respectively
      		                           57,730,000           
        common shares, chf 0.03 par value, 55,445,241 and 52,183,139 shares authorized at june 30, 2019 and december 31, 2018, respectively, 53,756,046 and 52,160,798 shares issued at june 30, 2019 and december 31, 2018, respectively, 53,499,057 and 51,852,862 shares outstanding at june 30, 2019 and december 31, 2018, respectively, 23,948,128 and 20,498,996 shares in conditional capital at june 30, 2019 and december 31, 2018, respectively.
      		                           1,630,000           
        treasury shares, at cost, 256,989 and 307,936 shares at june 30, 2019 and december 31, 2018, respectively
      		                           -57,000           
        accounts receivable, including related party amounts of 331 and 88 as of march 31, 2019 and december 31, 2018, respectively
      		                            331,000          
        prepaid expenses and other current assets, including related party amounts of 4,775 and 3,417 as of march 31, 2019 and december 31, 2018, respectively
      		                            11,916,000          
        accrued expenses, including related party amounts of 2,483 and 1,700 as of march 31, 2019 and december 31, 2018, respectively
      		                            15,680,000          
        deferred revenue non-current, including related party amounts of 57,755 and 57,780 as of march 31, 2019 and december 31, 2018, respectively
      		                            57,755,000          
        commitments and contingencies, see note 5
      		                                      
        common shares, chf 0.03 par value, 53,325,963 and 52,183,139 shares authorized at march 31, 2019 and december 31, 2018, respectively, 52,943,581 and 52,160,798 shares issued at march 31, 2019 and december 31, 2018, respectively, 52,635,645 and 51,852,862 shares outstanding at march 31, 2019 and december 31, 2018, respectively, 20,498,996 shares in conditional capital at march 31, 2019 and december 31, 2018.
      		                            1,589,000          
        treasury shares, at cost, 307,936 shares at march 31, 2019 and december 31, 2018
      		                            -57,000          
        cash
      		                             487,295,000 319,737,000 341,767,000 239,758,000 253,519,000 272,264,000 288,872,000 315,520,000 228,613,000 
        accounts receivable, including related party amounts of 457 and 821 as of september 30, 2018 and december 31, 2017, respectively
      		                             552,000         
        prepaid expenses and other current assets, including related party amounts of 52 and 1,871 as of september 30, 2018 and december 31, 2017, respectively
      		                             8,841,000         
        accrued expenses, including related party amounts of 234 and 0 as of september 30, 2018 and december 31, 2017, respectively
      		                             25,835,000         
        deferred revenue non-current, including related party amounts of 0 and 91 as of september 30, 2018 and december 31, 2017, respectively
      		                             57,806,000         
        common shares, chf 0.03 par value, 51,893,132 and 41,092,969 shares authorized at september 30, 2018 and december 31, 2017, respectively, 51,862,415 and 41,037,121 shares issued at september 30, 2018 and december 31, 2017, respectively, 51,554,479 and 40,592,248 shares outstanding at september 30, 2018 and december 31, 2017, respectively, 19,520,914 and 16,419,632 shares in conditional capital at september 30, 2018 and december 31, 2017, respectively.
      		                             1,575,000         
        treasury shares, at cost, 307,936 and 444,873 shares at september 30, 2018 and december 31, 2017, respectively
      		                             -57,000         
        accounts receivable, including related party amounts of 881 and 821 as of june 30, 2018 and december 31, 2017, respectively
      		                              944,000        
        prepaid expenses and other current assets, including related party amounts of 559 and 1,871 as of june 30, 2018 and december 31, 2017, respectively
      		                              9,868,000        
        accrued expenses, including related party amounts of 78 and 0 as of june 30, 2018 and december 31, 2017, respectively
      		                              12,702,000        
        deferred revenue non-current, including related party amounts of 0 and 91 as of june 30, 2018 and december 31, 2017, respectively
      		                              57,832,000        
        common shares, chf 0.03 par value, 47,520,292 and 41,092,969 shares authorized at june 30, 2018 and december 31, 2017, respectively, 47,481,196 and 41,037,121 shares issued at june 30, 2018 and december 31, 2017, respectively, 47,071,835 and 40,592,248 shares outstanding at june 30, 2018 and december 31, 2017, respectively, 19,699,821 and 16,419,632 shares in conditional capital at june 30, 2018 and december 31, 2017, respectively.
      		                              1,435,000        
        treasury shares, at cost, 409,361 and 444,873 shares at june 30, 2018 and december 31, 2017, respectively
      		                              -50,000        
        accounts receivable, including related party amounts of 1,006 and 821 as of march 31, 2018 and december 31, 2017, respectively
      		                               1,260,000       
        prepaid expenses and other current assets, including related party amounts of 605 and 1,871 as of march 31, 2018 and december 31, 2017, respectively
      		                               8,451,000       
        accrued expenses, including related party amounts of 78 and 0 as of march 31, 2018 and december 31, 2017, respectively
      		                               10,227,000       
        deferred revenue non-current, including related party amounts of 0 and 91 as of march 31, 2018 and december 31, 2017, respectively
      		                               57,858,000       
        common shares, chf 0.03 par value, 47,166,907 and 41,092,969 shares authorized at march 31, 2018 and december 31, 2017, respectively, 47,119,435 and 41,037,121 shares issued at march 31, 2018 and december 31, 2017, respectively, 46,680,815 and 40,592,248 shares outstanding at march 31, 2018 and december 31, 2017, respectively, 16,114,039 and 16,419,632 shares in conditional capital at march 31, 2018 and december 31, 2017, respectively
      		                               1,423,000       
        treasury shares, at cost, 438,620 and 444,873 shares at march 31, 2018 and december 31, 2017, respectively
      		                                      
        accounts receivable, including related party amounts of 821 and 752 as of december 31, 2017 and 2016, respectively
      		                                2,626,000      
        prepaid expenses and other current assets, including related party amounts of 1,871 and 0 as of december 31, 2017 and 2016, respectively
      		                                6,001,000      
        liabilities, redeemable convertible preferred shares and shareholders’ equity
      		                                      
        accrued expenses, including related party amounts of 0 and 537 as of december 31, 2017 and 2016, respectively
      		                                11,361,000      
        deferred revenue, including related party amounts of 91 and 527 as of december 31, 2017 and 2016, respectively
      		                                56,928,000      
        shareholders’ equity
      		                                      
        common shares, chf 0.03 par value, 41,092,969 and 40,253,674 shares authorized at december 31, 2017 and 2016, respectively, 41,037,121 and 40,164,307 shares issued at december 31, 2017 and 2016, respectively, 40,592,248, and 39,719,434 shares outstanding at december 31, 2017 and 2016, respectively, 16,419,632 and 15,325,607 shares in conditional capital at december 31, 2017 and 2016, respectively.
      		                                1,240,000      
        treasury shares, at cost, 444,873 shares and no shares at december 31, 2017 and 2016, respectively
      		                                      
        accounts receivable, including related party amounts of 1,133 and 752 as of september 30, 2017 and december 31, 2016, respectively
      		                                 3,211,000     
        prepaid expenses and other current assets, including related party amounts of 583 and 0 as of september 30, 2017 and december 31, 2016, respectively
      		                                 1,856,000     
        accrued expenses, including related party amounts of 0 and 537 as of september 30, 2017 and december 31, 2016, respectively
      		                                 8,485,000     
        deferred revenue, including related party amounts of 171 and 527 as of september 30, 2017 and december 31, 2016, respectively
      		                                 79,689,000     
        common shares, chf 0.03 par value, 40,890,954 and 40,253,674 shares authorized at september 30, 2017 and december 31, 2016, respectively, 40,826,727 and 40,164,307 shares issued at september 30, 2017 and december 31, 2016, respectively, 40,381,854 and 39,719,434 shares outstanding at september 30, 2017 and december 31, 2016, respectively, 16,746,246 and 15,325,607 shares in conditional capital at september 30, 2017 and december 31, 2016, respectively.
      		                                 1,234,000     
        treasury shares, at cost, 444,873 shares at september 30, 2017 and december 31, 2016, respectively
      		                                      
        accounts receivable, including related party amounts of 1,340 and 752 as of june 30, 2017 and december 31, 2016, respectively
      		                                  6,814,000    
        prepaid expenses and other current assets including related party amounts of 1,141 and 0 as of june 30, 2017 and december 31, 2016, respectively
      		                                  2,207,000    
        accrued expenses, including related party amounts of 305 and 537 as of june 30, 2017 and december 31, 2016, respectively
      		                                  11,888,000    
        deferred revenue, including related party amounts of 284 and 527 as of june 30, 2017 and december 31, 2016, respectively
      		                                  79,232,000    
        common shares, chf 0.03 par value, 40,556,891 and 40,253,674 shares authorized at june 30, 2017 and december 31, 2016, respectively, 40,484,288 and 40,164,307 shares issued at june 30, 2017 and december 31, 2016, respectively, 40,039,415 and 39,719,434 shares outstanding at june 30, 2017 and december 31, 2016, respectively, 17,079,353 and 15,325,607 shares in conditional capital at june 30, 2017 and december 31, 2016, respectively
      		                                  1,226,000    
        treasury shares, at cost, 444,873 shares at june 30, 2017 and december 31, 2016, respectively
      		                                      
        accounts receivable, including related party amounts of 1,057 and 752 as of march 31, 2017 and december 31, 2016, respectively
      		                                   5,672,000   
        prepaid expenses and other current assets including related party amounts of 577 and 0 as of march 31, 2017 and december 31, 2016, respectively
      		                                   1,918,000   
        accrued expenses, including related party amounts of 219 and 537 as of march 31, 2017 and december 31, 2016, respectively
      		                                   11,699,000   
        deferred revenue, including related party amounts of 420 and 527 as of march 31, 2017 and december 31, 2016, respectively
      		                                   78,311,000   
        common shares, chf 0.03 par value
      		                                   1,216,000   
        treasury shares, at cost, 444,873 shares at march 31, 2017 and december 31, 2016
      		                                      
        accounts receivable, including related party amounts of 752 and 0 as of december 31, 2016 and 2015, respectively
      		                                    3,157,000  
        accrued expenses, including related party amounts of 537 and 1,055 as of december 31, 2016 and 2015, respectively
      		                                    16,320,000  
        convertible loan, including accrued interest of 0 and 97 as of december 31, 2016 and 2015, respectively
      		                                      
        deferred revenue, including related party amounts of 527 and 0 as of december 31, 2016 and 2015, respectively
      		                                    77,646,000  
        redeemable convertible preferred shares:
      		                                      
        series a-1 redeemable convertible preferred shares, chf 0.03 par value, 0 and 440,001 shares authorized, issued, and outstanding in share capital at december 31, 2016 and 2015, respectively, aggregate liquidation preference of chf 0 and chf 502 at december 31, 2016 and 2015, respectively
      		                                      
        series a-2 redeemable convertible preferred shares, chf 0.03 par value, 0 and 3,120,001 shares authorized, issued, and outstanding in share capital at december 31, 2016 and 2015, respectively, aggregate liquidation preference of chf 0 and chf 9,512 at december 31, 2016 and 2015, respectively
      		                                      
        series a-3 redeemable convertible preferred shares, chf 0.03 par value, 0 and 10,758,006 shares authorized, issued, and outstanding in share capital at december 31, 2016 and 2015, respectively, aggregate liquidation preference of 0 and 22,850 at december 31, 2016 and 2015, respectively
      		                                      
        series b redeemable convertible preferred shares, chf 0.03 par value, 0 and 4,519,016 shares authorized, issued, and outstanding in share capital at december 31, 2016 and 2015, aggregate liquidation preference of chf 0 and chf 28,000 at december 31, 2016 and 2015, respectively
      		                                      
        common shares, chf 0.03 par value, 40,253,674, and 5,528,079 shares authorized at december 31, 2016 and 2015, respectively, 40,164,307 and 5,528,079 shares issued at december 31, 2016 and 2015, respectively, 39,719,434, and 5,528,079 shares outstanding at december 31, 2016 and 2015, respectively, 15,325,607 and 2,444,364 shares in conditional capital at december 31, 2016 and 2015, respectively
      		                                    1,216,000  
        treasury shares, at cost, 444,873 shares and no shares at december 31, 2016 and 2015, respectively
      		                                      
        total crispr therapeutics ag shareholders’ equity
      		                                    232,846,000  
        noncontrolling interest
      		                                     -51,000 
        total liabilities, redeemable convertible preferred shares and shareholders’ equity
      		                                    344,962,000  
        accounts receivable, including related party amounts of 459 and 0 as of september 30, 2016 and december 31, 2015, respectively
      		                                     2,092,000 
        equity method investment
      		                                     35,686,000 
        liabilities, redeemable convertible preferred shares and shareholders’ deficit
      		                                      
        deferred gain
      		                                     63,608,000 
        convertible loan, including accrued interest of 0 and 97 as of september 30, 2016 and december 31, 2015, respectively
      		                                      
        deferred revenue
      		                                     76,949,000 
        series a-1 redeemable convertible preferred shares, chf 0.03 par value, 440,001 shares authorized, issued, and outstanding in share capital at september 30, 2016, and december 31, 2015, respectively; aggregate liquidation preference of chf 502 and chf 502 at september 30, 2016 and december 31, 2015, respectively
      		                                     1,169,000 
        series a-2 redeemable convertible preferred shares, chf 0.03 par value, 3,120,001 shares authorized, issued, and outstanding in share capital at september 30, 2016, and december 31, 2015, respectively; aggregate liquidation preference of chf 9,512 and chf 9,512 at september 30, 2016 and december 31, 2015, respectively
      		                                     10,394,000 
        series a-3 redeemable convertible preferred shares, chf 0.03 par value, 0, 10,758,006 shares authorized, issued, and outstanding in share capital at september 30, 2016 and december 31, 2015, respectively; aggregate liquidation preference of 45,700 and 22,850 at september 30, 2016 and december 31, 2015, respectively
      		                                     45,368,000 
        series b redeemable convertible preferred shares, chf 0.03 par value, 12,817,876 and 4,519,016 shares authorized, issued, and outstanding in share capital at september 30, 2016 and december 31, 2015, respectively; aggregate liquidation preference of chf 28,000 and 111,487, and chf 28,000 at september 30, 2016 and december 31, 2015, respectively
      		                                     128,634,000 
        shareholders’ deficit:
      		                                      
        common shares, chf 0.03 par value, 5,662,126 shares authorized and issued, and 5,307,845 shares outstanding, and 5,528,079 shares authorized, issued and outstanding in share capital at september 30, 2016 and december 31, 2015, respectively; 38,453,593 and 2,444,364 shares in conditional capital at september 30, 2016 and december 31, 2015, respectively
      		                                     174,000 
        treasury shares, at cost; 274,184 shares at september 30, 2016 and no shares at december 31, 2015
      		                                      
        total crispr therapeutics ag shareholders’ deficit
      		                                     -62,481,000 
        total shareholders’ deficit
      		                                     -62,532,000 
        total liabilities, redeemable convertible preferred shares and shareholders’ deficit
      		                                     278,653,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 
                                             
          operating activities:
        		                                     
          net loss
        		-122,931,000 -130,613,000 -106,441,000 -208,549,000 -135,996,000 -37,311,000 -85,942,000 -126,408,000 -116,591,000  -112,152,000 -77,740,000 -53,065,000    -179,217,000    -113,163,000  -92,439,000 -79,656,000 -69,731,000             
          reconciliation of net loss to net cash from operating activities:
        		                                     
          depreciation and amortization
        		4,319,000 5,661,000 4,433,000 4,649,000 4,736,000 4,842,000 4,739,000 4,845,000 4,833,000 4,900,000 4,925,000 4,961,000 5,051,000 5,846,000 5,018,000 7,269,000 6,039,000 6,261,000 5,324,000 3,653,000 2,715,000 2,566,000 2,335,000 2,192,000 2,091,000 1,432,000 1,283,000 1,198,000 812,000 883,000 865,000 826,000 806,000 792,000 706,000 720,000  
          equity-based compensation
        		16,324,000  16,604,000 17,607,000 20,212,000  21,543,000 23,672,000 19,405,000 18,420,000 19,968,000 21,765,000 20,875,000 22,805,000 24,545,000 24,852,000 25,745,000 25,768,000 26,199,000 28,331,000 22,092,000 18,930,000 17,240,000 15,697,000 14,151,000 11,857,000 11,343,000 11,186,000 9,671,000 8,054,000 8,324,000 5,582,000 6,979,000 4,868,000 3,280,000 3,746,000  
          other non-cash items
        		8,800,000 -8,314,000 -10,139,000 -7,328,000 2,253,000 -15,155,000 -6,897,000 -8,181,000 -8,385,000 -4,766,000 -6,159,000 -4,651,000 -969,000 219,000 2,580,000 3,572,000 6,099,000                     
          changes in:
        		                                     
          accounts receivable
        		 0 0 0 25,000,000 -25,000,000 0 0 200,000,000     49,000 17,000 77,000 162,000 -153,000 -2,000 0 -6,000 -34,000 -77,000 25,084,000 -25,018,000 -60,000 282,000 10,000 -243,000 392,000 316,000 1,366,000 585,000 3,603,000 -1,142,000 -2,515,000 -1,065,000 
          prepaid expenses and other assets
        		-247,000 3,852,000 212,000 -93,000 -634,000 176,000 -188,000 2,348,000 2,949,000 6,450,000 817,000 3,912,000 12,040,000 -5,464,000 5,030,000 -2,579,000 4,611,000 4,863,000 -9,305,000 -4,402,000 -5,068,000 -1,935,000 -4,322,000 -6,064,000 29,659,000 -7,276,000 -23,943,000 1,652,000 -3,051,000 1,302,000 -1,378,000 -2,426,000 -3,813,000 432,000 -342,000 -394,000 -377,000 
          accounts payable and accrued expenses
        		-13,015,000 4,421,000 12,175,000 -14,700,000 42,998,000 -7,850,000 -38,157,000 9,281,000 9,443,000 -9,191,000 -24,693,000 -11,577,000 25,214,000 -31,097,000 27,958,000 9,919,000 -1,616,000 22,781,000 1,306,000 19,197,000 -5,770,000 8,353,000 4,178,000 15,712,000 -2,496,000 4,605,000 1,269,000 2,475,000 -3,324,000 4,218,000 4,203,000 -439,000 2,148,000 -876,000 1,545,000 -3,648,000 585,000 
          deferred revenue
        		-427,000 2,153,000 -834,000 -892,000 -824,000 -638,000 -536,000 -271,000 -504,000 -1,206,000    -249,000 249,000 -249,000 -762,000 -4,000 -508,000 268,000 -539,000 1,731,000 -149,000 -44,000 -157,000 -46,860,000 1,764,000 -25,000 -25,000 -26,000 -26,000 -218,000 -22,761,000 457,000 921,000 665,000 697,000 
          operating lease assets and liabilities
        		-1,521,000 -1,343,000 -1,446,000 -1,270,000 -1,151,000 -1,027,000 -1,506,000 -908,000 -966,000 -732,000 -452,000 -1,100,000 -177,000 4,484,000 4,961,000 2,011,000 3,854,000 -10,173,000 18,420,000 481,000 778,000 -191,000 -171,000 -148,000 37,000 26,000 -298,000           
          other liabilities
        		-199,000 13,554,000 802,000 443,000 -10,541,000 9,985,000 31,000 40,000 -432,000 705,000 -110,000 -315,000 -170,000 654,000 -1,027,000 -994,000 -154,000 1,178,000 -613,000 -2,104,000 -3,766,000 -4,471,000 -2,385,000 -2,051,000 -1,601,000 25,110,000 -133,000 200,000 -194,000 -50,000 63,000 25,000 239,000 -247,000 274,000 4,000 -28,000 
          net cash from operating activities
        		-108,897,000 -92,553,000 -84,634,000 -113,880,000 -53,947,000 -50,031,000 -106,913,000 -95,582,000 109,752,000 -96,073,000 -39,856,000 -133,245,000 8,799,000 -113,328,000 -105,218,000 -141,956,000 -135,239,000 -86,038,000 -81,329,000 807,002,000 -100,663,000 -81,212,000 -75,700,000 -29,279,000 -52,175,000 3,376,000 133,420,000 -36,382,000 -43,737,000    -14,842,000 -15,868,000 -15,975,000 -23,412,000 -19,416,000 
          capital expenditures
        		-504,000 -517,000 -74,000 -117,000 -206,000 -254,000 -219,000 -707,000 -721,000 -738,000 -2,118,000 -3,555,000 -3,059,000 -6,191,000 -6,017,000 -9,630,000 -15,350,000 -9,183,000 -37,049,000 -28,449,000 -7,024,000 -6,239,000 0 -3,605,000 -2,991,000 -952,000 -2,461,000 -2,174,000 -1,097,000    -205,000 -2,994,000 -1,330,000 -3,285,000 -228,000 
          free cash flows
        		-109,401,000 -93,070,000 -84,708,000 -113,997,000 -54,153,000 -50,285,000 -107,132,000 -96,289,000 109,031,000 -96,811,000 -41,974,000 -136,800,000 5,740,000 -119,519,000 -111,235,000 -151,586,000 -150,589,000 -95,221,000 -118,378,000 778,553,000 -107,687,000 -87,451,000 -75,700,000 -32,884,000 -55,166,000 2,424,000 130,959,000 -38,556,000 -44,834,000    -15,047,000 -18,862,000 -17,305,000 -26,697,000 -19,644,000 
          investing activities:
        		                                     
          purchase of property, plant and equipment
        		-504,000 -517,000 -74,000 -117,000 -206,000 -254,000 -219,000 -707,000 -721,000 -738,000 -2,118,000 -3,555,000 -3,059,000 -6,191,000 -6,017,000 -9,630,000 -15,350,000 -9,183,000 -37,049,000 -28,449,000 -7,024,000 -6,239,000                
          investment in equity securities
        		-4,615,000 0 0 -4,700,000 -5,000,000 -2,798,000 -7,500,000 -5,385,000 -7,500,000                             
          purchases of marketable securities
        		-746,089,000  -334,086,000 -210,381,000 -200,730,000  -401,563,000 -470,594,000 -326,915,000 -368,149,000 -245,399,000 -186,736,000 -265,627,000 -494,396,000 -326,268,000 -273,996,000 -323,140,000 -122,542,000 -670,803,000 -392,007,000 -323,975,000 -268,682,000                
          maturities of marketable securities
        		192,759,000  214,934,000 310,175,000 186,181,000  247,678,000 349,781,000 237,336,000 287,434,000 369,865,000 408,714,000 386,515,000 325,055,000 419,749,000 227,554,000 223,975,000 123,009,000 142,672,000 126,820,000 163,101,000 70,677,000                
          sales of marketable securities
        		147,706,000                                     
          net cash from investing activities
        		-410,743,000  -119,226,000 69,977,000 -19,755,000 105,828,000 -161,604,000 -126,905,000 -97,800,000 -81,453,000 121,348,000 216,923,000 117,829,000 -175,532,000 87,464,000 -56,072,000 -114,515,000 -8,716,000 -565,180,000 -293,636,000 -167,898,000 -204,244,000 -330,330,000 -3,605,000 -2,991,000 7,057,000 -2,461,000 -2,174,000 -1,097,000    -205,000 -3,494,000 -1,330,000 -3,285,000 14,772,000 
          financing activities:
        		                                     
          proceeds from issuance of the notes
        		600,000,000                                     
          issuance costs and discounts associated with the notes
        		-13,528,000                                     
          proceeds from issuance of common shares, net of issuance costs
        		-722,000 111,491,000 278,105,000 -22,000 8,516,000 14,959,000 6,003,000 -1,012,000 280,745,000     0    0 0 -1,325,000 214,592,000 400,064,000 499,204,000   293,803,000 68,922,000 28,400,000 23,894,000         
          proceeds from exercise of options and espp contributions, net of issuance costs
        		6,158,000 4,923,000 18,661,000 2,280,000 2,072,000 1,917,000 3,637,000 546,000 25,189,000 6,218,000 1,556,000 16,765,000 5,404,000 2,478,000 14,142,000 10,353,000 10,649,000 6,299,000 10,212,000 9,768,000 11,399,000 12,563,000                
          net cash from financing activities
        		591,908,000 116,414,000 296,766,000 2,258,000 10,588,000 16,876,000 9,640,000 -466,000 305,934,000 38,939,000 1,556,000 16,765,000 5,404,000 2,478,000 15,112,000 10,353,000 10,649,000 6,299,000 10,212,000 8,443,000 225,991,000 412,627,000 512,888,000 89,505,000 1,132,000 304,718,000 70,885,000 29,654,000 25,726,000 188,223,000 3,729,000 125,251,000 1,284,000 609,000 695,000 20,000 91,766,000 
          effect of exchange rate changes on cash
        		-32,000 1,000 -27,000 80,000 41,000 -87,000 75,000 2,000 -11,000 61,000 -48,000 28,000 32,000 115,000 -100,000 -68,000 -27,000 3,000 -24,000 5,000 5,000 35,000 33,000 -3,000 -25,000 29,000 -12,000 -10,000 8,000 -6,000 -21,000 12,000 2,000 8,000 2,000 29,000 -215,000 
          increase in cash
        		72,236,000   -41,565,000 -63,073,000 72,586,000 -258,802,000 -222,951,000 317,875,000 -138,526,000 83,000,000 100,471,000 132,064,000     -88,452,000 -636,321,000   127,206,000 106,891,000   315,180,000 201,832,000 -8,912,000 -19,100,000    -13,761,000 -18,745,000 -16,608,000 -26,648,000 86,907,000 
          cash, cash equivalents and restricted cash, beginning of period
        		359,078,000 0 0 0 309,776,000 0 0 0 401,068,000 0 0 0 224,060,000 0 0 0 939,944,000 0 0 0 1,185,468,000 0 0 0 948,812,000 0 0 0 459,812,000         
          cash, cash equivalents and restricted cash, end of period
        		431,314,000 61,061,000 92,879,000 -41,565,000 246,703,000 72,586,000 -258,802,000 -222,951,000 718,943,000 -138,527,000 83,000,000 100,471,000 356,124,000 -286,267,000 -2,742,000 -187,743,000 700,812,000 -88,452,000 -636,321,000 521,814,000 1,142,903,000 127,206,000 106,891,000 56,618,000 894,753,000 315,180,000 201,832,000 -8,912,000 440,712,000         
          supplemental disclosure of non-cash investing and financing activities
        		                                     
          equity issuance costs in accounts payable, accrued expenses, and other long-term liabilities
        		4,140,000  2,781,000 680,000 3,219,000  -24,000 -1,493,000 4,522,000                             
          issuance costs associated with the notes in accounts payable and accrued expenses
        		1,122,000                                     
          operating activities
        		                                     
          stock-based compensation expense
        		                                     
          acquired in-process research and development
        		 0 0       0 1,000,000                           
          investing activities
        		                                     
          purchase of in-process research and development
        		 0 0       0 -1,000,000                           
          sale of equity securities
        		                                     
          purchases of marketable debt securities
        		                                     
          maturities of marketable debt securities
        		                                     
          net cash from (provided by) investing activities
        		                                     
          financing activities
        		                                     
          property and equipment purchases in accounts payable and accrued expenses
        		     121,000 13,000 -111,000 131,000 -28,000 -276,000 -1,634,000 2,663,000 -2,798,000 -97,000 -872,000 5,888,000 2,084,000 -1,269,000 -1,314,000 8,847,000 549,000 278,000 1,245,000 1,340,000 1,383,000 -274,000 123,000 579,000  -182,000 307,000  -2,579,000 1,724,000 973,000 6,768,000 
          equity issuance costs in accounts payable and accrued expenses
        		         407,000 -283,000 138,000 155,000 -200,000 58,000 24,000 217,000 -57,000 -11,000 -2,466,000 2,868,000 3,635,000 4,946,000 970,000 39,000  262,000 296,000 181,000         
          acquired in-process research and development expense related to issuance of common shares
        		 0 0                                   
          decrease in cash
        		                -239,132,000    -42,565,000    -54,059,000             
          stock-based compensation
        		                                     
          net income
        		             -110,575,000 -174,549,000   -141,248,000 -127,153,000       30,542,000   -48,408,000 -50,711,000 -38,380,000 -28,300,000 141,000 -24,708,000 -22,315,000 -21,475,000 17,098,000 
          reconciliation of net income to net cash from operating activities:
        		                                     
          leasehold improvements paid directly by landlord
        		              0 6,237,000 13,015,000                     
          loss from equity method investment in casebia
        		                                     
          gain from consolidation of casebia
        		                                     
          net amortization of premiums and discounts on marketable securities
        		                                     
          net cash and restricted cash received in connection with the acquisition of casebia
        		                                     
          other income, non-cash
        		                  5,003,000 2,353,000 2,064,000         0        
          non-cash expense related to viacyte transaction
        		                                     
          deferred rent
        		                             -147,000 -186,000 -195,000 381,000 -548,000 160,000 -515,000 2,164,000 
          repurchase of treasury shares
        		                                     
          loss from equity method investment
        		                          3,430,000           
          other expense, non-cash
        		                      90,000 -1,000 890,000             
          purchase of property and equipment
        		                       -3,605,000 -2,991,000 -952,000 -2,461,000 -2,174,000 -1,097,000 -695,000 -523,000 -555,000 -205,000 -2,994,000 -1,330,000 -3,285,000 -228,000 
          proceeds from exercise of options, net of issuance costs
        		                       6,484,000 1,132,000             
          purchase of available for sale debt security
        		                                0     
          stock option issuance costs included in accrued expenses
        		                                     
          costs for proposed supplemental offering in accounts payable and accrued expenses
        		                                     
          expense related to viacyte transaction
        		                                     
          proceeds from exercise of options
        		                          1,963,000 1,254,000 1,832,000 1,808,000 3,779,000 2,654,000 1,284,000 609,000 695,000 20,000  
          income from equity method investment
        		                            1,025,000 1,012,000 1,153,000 1,091,000 453,000 359,000   35,694,000 
          reconciliation of net income to net cash and restricted cash from operating activities:
        		                                     
          unrealized foreign currency remeasurement loss
        		                                 0 -10,000 1,000 9,000 
          net cash and restricted cash (used in) operating activities
        		                             -19,964,000        
          net cash and restricted cash (used in) investing activities
        		                             -695,000        
          repurchase of common shares
        		                                     
          increase in cash and restricted cash
        		                             167,558,000 -22,030,000 102,020,000      
          cash and restricted cash, beginning of period
        		                             0 0 242,912,000      
          cash and restricted cash, end of period
        		                             167,558,000 -22,030,000 344,932,000      
          costs for supplemental offering in accounts payable and accrued expenses
        		                                     
          proceeds from issuance of common shares in secondary offering, net of issuance
        		                              0 122,597,000      
          net cash and restricted cash from operating activities
        		                               -22,688,000      
          net cash and restricted cash from investing activities
        		                               -555,000      
          non-cash interest
        		                                     
          unrealized foreign currency remeasurement (gain) loss
        		                                     
          gain on extinguishment of convertible loan
        		                                    0 
          other income - formation of joint venture
        		                                     
          restricted cash
        		                                0 0 -3,000 -1,000 3,000 
          proceeds from contribution of intellectual property to equity method investee
        		                                    15,000,000 
          cash investment in equity method investee
        		                                    0 
          proceeds from issuance of common shares in ipo, net of issuance costs
        		                                     
          proceeds from issuance of common shares in private placement
        		                                     
          proceeds from issuance of restricted shares
        		                                     
          proceeds from issuance of series a-2 preferred shares
        		                                     
          proceeds from issuance of series a-3 preferred shares
        		                                    0 
          proceeds from issuance of series b preferred shares
        		                                    0 
          issuance costs for preferred share financings
        		                                    0 
          proceeds from issuance of convertible loans
        		                                    10,000 
          cash, beginning of period
        		                                0 0 0 315,520,000 0 
          cash, end of period
        		                                -13,761,000 -18,745,000 -16,608,000 288,872,000 86,907,000 
          property and equipment related to lease incentives
        		                                     
          conversion of preferred shares to common shares upon ipo
        		                                     
          conversion of vertex and bayer convertible loans and accrued interest
        		                                    0 
          issuance costs for public offering in accounts payable and accrued expenses
        		                                     
          contribution of intellectual property to casebia
        		                                     
          income from disposal of property and equipment
        		                                     
          proceeds from issuance of common shares
        		                                     
          payment of public offering costs
        		                                     
          conversion of vertex convertible loan and accrued interest
        		                                     
          noncash contribution of intellectual property to casebia therapeutics llp
        		                                     
          noncash contribution of intellectual property to casebia llp
        		                                     
          non-cash interest expense
        		                                    0 
          depreciation and amortization expense
        		                                    412,000 
          equity-based compensation expense
        		                                    4,028,000 
          loss on extinguishment of series a-1 preferred shares
        		                                     
          noncontrolling interest upon consolidation of tracr
        		                                     
          payment of proposed public offering costs
        		                                     
          costs for proposed public offering in accounts payable and accrued expenses